Additionally, people taking semaglutide lost about 5% of their body weight during the study, while those on placebo didnt lose weight
Insurance may cover GLP-1 medications for weight loss, but coverage is inconsistent
Results of a late-stage trial show that Type 2 diabetes patients using Eli Lillys highly anticipated next-generation weight-loss drug retatrutide experienced a significant reduction in blood-sugar levels and weight loss, the drug manufacturer said last week
Summary: GLP-1 receptor agonists are associated with modest increases in resting heart rate, typically 24 beats per minute, which have not been linked to increased cardiovascular risk
We pair GLP-1 therapy with muscle-protective peptides so the weight you lose is fat, not lean mass and we design a structured off-ramp so you come off the medication cleanly instead of staying on it forever
Halsz P, Klviinen R, Mazurkiewicz-Beldziska M, Rosenow F, Doty P, Hebert D, et al